Life sciences technology vendors and consultancies are busy
promoting identification of medicinal products (IDMP) compliance
solutions, which seems odd, given that many details of the final
requirements have yet to be published. With a further two years to
go until the latest deadline comes around, organisations have every
reason to be sceptical of the value of investing now, says Marc
Chaillou, International Markets Manager at Schlafender Hase.